Warning! GuruFocus detected
2 Severe warning signs
with IPD.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Impedimed Ltd
SIC : 3840
ISIN : AU000000IPD8
Description
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.92 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.22 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.6 | |||||
| 3-Year EBITDA Growth Rate | 15.1 | |||||
| 3-Year EPS without NRI Growth Rate | 16.2 | |||||
| 3-Year FCF Growth Rate | 8.4 | |||||
| 3-Year Book Growth Rate | 5.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 65.46 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.67 | |||||
| 9-Day RSI | 42.3 | |||||
| 14-Day RSI | 41.16 | |||||
| 3-1 Month Momentum % | -15.69 | |||||
| 6-1 Month Momentum % | -25.86 | |||||
| 12-1 Month Momentum % | -53.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.57 | |||||
| Quick Ratio | 4.39 | |||||
| Cash Ratio | 3.49 | |||||
| Days Inventory | 222.9 | |||||
| Days Sales Outstanding | 74.59 | |||||
| Days Payable | 448.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | 0.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.65 | |||||
| Operating Margin % | -206.41 | |||||
| Net Margin % | -187.32 | |||||
| FCF Margin % | -179.34 | |||||
| ROE % | -51.31 | |||||
| ROA % | -43.97 | |||||
| ROIC % | -114.73 | |||||
| 3-Year ROIIC % | -21.16 | |||||
| ROC (Joel Greenblatt) % | -1360.88 | |||||
| ROCE % | -54.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.99 | |||||
| PB Ratio | 2.64 | |||||
| Price-to-Tangible-Book | 4.2 | |||||
| EV-to-EBIT | -2.92 | |||||
| EV-to-Forward-EBIT | -5.05 | |||||
| EV-to-EBITDA | -3.41 | |||||
| EV-to-Forward-EBITDA | -5.82 | |||||
| EV-to-Revenue | 6.04 | |||||
| EV-to-Forward-Revenue | 5.48 | |||||
| EV-to-FCF | -3.37 | |||||
| Price-to-GF-Value | 0.35 | |||||
| Price-to-Median-PS-Value | 0.35 | |||||
| Price-to-Net-Current-Asset-Value | 4.2 | |||||
| Price-to-Net-Cash | 4.2 | |||||
| Earnings Yield (Greenblatt) % | -34.13 | |||||
| FCF Yield % | -23.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Impedimed Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 11.327 | ||
| EPS (TTM) (A$) | -0.011 | ||
| Beta | 2.29 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.29 | ||
| Volatility % | 41.83 | ||
| 14-Day RSI | 41.16 | ||
| 14-Day ATR (A$) | 0.001857 | ||
| 20-Day SMA (A$) | 0.0427 | ||
| 12-1 Month Momentum % | -53.26 | ||
| 52-Week Range (A$) | 0.0405 - 0.105 | ||
| Shares Outstanding (Mil) | 2,025.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Impedimed Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Impedimed Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Impedimed Ltd Frequently Asked Questions
What is Impedimed Ltd(ASX:IPD)'s stock price today?
The current price of ASX:IPD is A$0.04. The 52 week high of ASX:IPD is A$0.11 and 52 week low is A$0.04.
When is next earnings date of Impedimed Ltd(ASX:IPD)?
The next earnings date of Impedimed Ltd(ASX:IPD) is .
Does Impedimed Ltd(ASX:IPD) pay dividends? If so, how much?
Impedimed Ltd(ASX:IPD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers